TABLE 5.

Analysis of g209-2M Peptide-Vaccinated Patient PBMC 1 Year After Immunization

	% g209-Specific of CD8+ T Cells*		Peptide-Induced Proliferation†			Cytolytic Activity‡
Patient	Post 4	1 year	g280	g209	P	g280	g209	P
1	12.4	5.0	11,905 ± 714	18,663 ± 1371	<0.05	62.6 ± 3.4	63.6 ± 4.7	n.s.
2	5.6	0.8	10,208 ± 259	15,069 ± 1809	<0.05	12.0 ± 2.1	11.1 ± 1.5	n.s.
3	6.6	2.0	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
5	38.2	25.4	8646 ± 1366	25,259 ± 481	<0.05	13.1 ± 0.8	51.8 ± 1.4	<0.05

Tetramer and functional assays on 1-year postimmunization PBMC were performed concurrently with preimmune and course 4 samples.

^*Values correspond to the number of gated CD8⁺ tetramer⁺ cells divided by the number of total CD8^bright cells minus the CD8^- tetramer⁺ background (number of CD8^- tetramer⁺ cells divided by total CD8^- cell number) × 100.

^†Values reflect the average counts per minute ± s.e.m. of 3 replicate well cocultures containing 2 × 10⁵ PBMC and an equal number of irradiated T2 cells (20,000 rad) pulsed with 1 μM of g209 or g280 peptide in a 3-day [³H]-thymidine incorporation assay.

^‡Values represent the mean percent lysis from triplicate wells ± s.e.m. at a 100:1 effector to 1 μM peptide-pulsed target cell ratio in a standard 4-hour ⁵¹Cr-release assay. Significance values >0.05 are indicated as n.s.